Table 4.
Number and distribution of relevant adverse events and eGFR.
| Adverse Event. | TAC (n = 22) | SRL (n = 20) | ||
|---|---|---|---|---|
| General | Weight Loss | 2 (9.1%) | 0 | 0.489 |
| Oedema of Both Legs | 0 | 1 (4.2%) | 0.476 | |
| Wound Complication | 0 | 2 (10%) | 0.221 | |
| Wound Lymphocele | 0 | 1 (4.2%) | 0.476 | |
| Umbilical Hernia | 0 | 1 (4.2%) | 0.476 | |
| Cardiovascular | Haemolytic Anaemia | 1 (4.5%) | 1 (4.2%) | 1.000 |
| HTN | 2 (9.1%) | 2 (10%) | 1.000 | |
| Dyslipidaemia | 0 | 3 (15%) | 0.099 | |
| Gastrointestinal | LFT Abnormality | 1 (4.5%) | 0 | 1.000 |
| Diffuse Fatty Liver | 1 (4.5%) | 0 | 1.000 | |
| Biliary Stricture | 2 (9.1%) | 2 (10%) | 1.000 | |
| Oral Mucositis | 0 | 2 (8.3%) | 0.221 | |
| Diarrhoea | 1 (4.5%) | 1 (4.2%) | 1.000 | |
| Dermatologic | Scaled Skin, Rash | 1 (4.5%) | 2 (8.3%) | 0.598 |
| Hyperpigmentation | 1 (4.5%) | 0 | 1.000 | |
| Infection | Herpes Zoster | 0 | 1 (5%) | 0.476 |
| Pulmonary Tb | 0 | 1 (5%) | 0.476 | |
| Radiation- and Nexavar-Related Symptom (Diarrhoea, Hand-Foot Syndrome) |
0 | 1 (5%) | 0.476 | |
| eGFR (MDRD) | ||||
| Initial | 92.3 ± 27.7 | 103.1 ± 30.1 | 0.24 | |
| 1 Year | 80.9 ± 28.9 | 95.8 ± 23.2 | 0.08 | |
| 2 Years | 80.5 ± 27.5 | 95.6 ± 26.7 | 0.09 | |
| 3 Years | 74.9 ± 25.0 | 90.2 ± 25.3 | 0.08 |
eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease equation; TAC, tacrolimus; SRL, sirolimus; HTN, hypertension; LFT, liver function test; Tb, tuberculosis.